New Directions in Managing Dyslipidemia

Statin therapy has long been the mainstay of dyslipidemia management due to superior reduction in morbidity and mortality from cardiovascular disease. However, many patients who take statins fail to meet low-density lipoprotein-cholesterol targets, have recurrent atherosclerotic cardiovascular disea...

Full description

Saved in:
Bibliographic Details
Published in:Journal for nurse practitioners 2019-01, Vol.15 (1), p.73-79.e2
Main Author: Palmer, Carrie
Format: Article
Language:English
Subjects:
Atherosclerosis
Cardiovascular disease
Cardiovascular diseases
Cholesterol
Diabetes
Disease management
Disease prevention
Drug therapy
dyslipidemia
Lipoproteins
Liver diseases
Metabolic disorders
Morbidity
Mortality
Nurse practitioners
Patients
PCSK9 inhibitor
Recurrent
statin
Statins
Triglycerides
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Statin therapy has long been the mainstay of dyslipidemia management due to superior reduction in morbidity and mortality from cardiovascular disease. However, many patients who take statins fail to meet low-density lipoprotein-cholesterol targets, have recurrent atherosclerotic cardiovascular disease, or are statin intolerant. Recent updates give guidance on prevention of atherosclerotic cardiovascular disease in all patients, including those for whom statin therapy is contraindicated or insufficient. Other classes of medications, such as ezetimibe and proprotein convertase subtilisin/kexin type 9 inhibitors, can lower low-density lipoprotein cholesterol and may also improve cardiovascular outcomes. This report explores dyslipidemia management guidelines, reviews the use of ezetimibe and proprotein convertase subtilisin/kexin type 9 inhibitors, and provides recommendations for nurse practitioners. •Atherosclerotic cardiovascular disease remains a leading cause of death in the United States.•Statins are the mainstay of therapy to reduce atherosclerotic cardiovascular disease,•Ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are recommended second-line agents.
ISSN:1555-4155
1878-058X
DOI:10.1016/j.nurpra.2018.08.033